Women with breast cancer who receive higher doses of radiation with IMRT each day can reduce their treatment time by two weeks without increasing side effects, according to a study released today in the June 1 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Therapeutic Radiology and Oncology.
Radiation therapy after lumpectomy for early-stage breast cancer can be safely delivered in higher daily doses to greatly reduce treatment time. This conclusion of a new Fox Chase Cancer Center study is good news for women who might opt to have a mastectomy instead of a lumpectomy because of the time commitment needed for the usual six-week radiation course with the breast-sparing surgical option.
Results of a world-first, large-scale study of faulty genes and breast cancer, with significant Australian contributions including research from the University of Melbourne will be released in Nature today.
A genetic mutation that raises the risk of breast cancer is found in up to 60 percent of U.S. women, making it the first truly common breast cancer susceptibility gene.
Follow-up of breast cancer patients after their initial treatment is becoming “devalued and deregulated”, according to new research published online in the cancer journal, Annals of Oncology.
Researchers at the Abramson Family Cancer Research Institute of the University of Pennsylvania and the Dana-Farber Cancer Institute describe in this week?s issue of Science a new candidate breast-cancer susceptibility gene. The Rap80 gene is required for the normal DNA-repair function of the well-known breast cancer gene BRCA1.
New published data from a large pan-European survey indicate that the majority of postmenopausal women with early breast cancer taking post-surgical endocrine therapy are not involved in making key decisions about their treatment, nor are they given sufficient information to make informed treatment choices that could affect their long-term outcome.
GlaxoSmithKline announced an important milestone for advanced breast cancer patients across Europe with approval of the first oral ErbB1 and ErbB2 dual inhibitor, Tyverb? (lapatinib).
Are soy products healthy additions to a person?s diet, safe alternatives to hormone-replacement therapy or cancer-causing agents? The answer, according to University of Illinois food science and human nutrition professor William Helferich, is, “It depends.”
Researchers have identified genetic markers on several chromosomes in the tissue surrounding tumor cells that are associated with breast cancer tumor grade and the presence of lymph node metastases, according to a study in the May 16 issue of JAMA.